Board Meeting Details

The Board of Directors meeting was held on Monday, September 21, 2026. The meeting commenced at 03:30 p.m. and concluded at 04:45 p.m. The Board considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026.

Trading Window Closure

The Trading Window for dealing in Company's securities shall remain closed until 48 hours from this announcement.

Consolidated Financial Results (₹ in Million)

Income Statement - Consolidated

  • Revenue from operations: ₹2,181.50 (Q1 FY27) vs ₹2,031.72 (Q1 FY26)
  • Other income: ₹3.38 (Q1 FY27) vs ₹26.41 (Q1 FY26)
  • Total Income: ₹2,184.88 (Q1 FY27) vs ₹2,068.13 (Q1 FY26)

Expenses - Consolidated

  • Cost of raw materials, packing material and consumables consumed: ₹755.59
  • Employee benefit expenses: ₹464.21
  • Finance costs: ₹61.79
  • Depreciation and amortization expense: ₹218.24
  • Other expenses: ₹509.73
  • Total expenses: ₹2,009.56

Profitability - Consolidated

  • Profit before exceptional item and tax: ₹175.32
  • Exceptional items: None in current quarter (Previous year: ₹89.93 impact of New wages code on Gratuity and Leave encashment)
  • Profit before tax: ₹176.32
  • Income tax expense: ₹34.71 (Current tax: ₹160.20, Deferred tax credit: ₹125.49)
  • Net Profit for the period: ₹140.61
  • Total comprehensive income for the period: ₹141.27

Earnings Per Share - Consolidated

  • Basic EPS: ₹2.24 (not annualized)
  • Diluted EPS: ₹2.24 (not annualized)

Attribution - Consolidated

  • Net Profit attributable to Owners of the Parent Company: ₹140.58
  • Net Profit attributable to Non-controlling interests: ₹0.05

Standalone Financial Results (₹ in Million)

Income Statement - Standalone

  • Revenue from operations: ₹2,108.43 (Q1 FY27) vs ₹2,042.62 (Q1 FY26)
  • Other income: ₹195.47 (Q1 FY27) vs ₹114.74 (Q1 FY26)
  • Total Income: ₹2,303.90 (Q1 FY27) vs ₹2,157.36 (Q1 FY26)

Expenses - Standalone

  • Cost of raw materials, packing material and consumables consumed: ₹783.97
  • Employee benefit expenses: ₹352.20
  • Finance costs: ₹56.20
  • Depreciation and amortization expense: ₹101.47
  • Other expenses: ₹379.86
  • Total expenses: ₹1,873.70

Profitability - Standalone

  • Profit before exceptional items and tax: ₹630.20
  • Exceptional items: None in current quarter (Previous quarter: ₹528.13 provision for impairment)
  • Profit before tax: ₹630.20
  • Income tax expense: ₹160.12 (Current tax: ₹160.20, Deferred tax credit: ₹0.08)
  • Net Profit for the period: ₹470.08
  • Total comprehensive income for the period: ₹469.59

Earnings Per Share - Standalone

  • Basic EPS: ₹7.49 (not annualized)
  • Diluted EPS: ₹7.49 (not annualized)

Share Capital

  • Paid-up equity share capital: 62,734,851 equity shares of face value ₹2/- each

Subsidiary Information

The consolidated results include financial results of 7 entities:

1. Symbiotec Pharmalab Limited (Holding Company)

2. Knovea Pharmaceuticals Private Limited (Subsidiary of SPL)

3. Symbiotec Zenfold Private Limited (Subsidiary of SPL)

4. Navisci Pte Limited (Subsidiary of SPL)

5. Xinjiang Symbiotec Biotechnology Limited (Subsidiary of SPL)

6. Symbiotec Biologics Private Limited (Subsidiary of SPL)

7. Xenamed Corp (Subsidiary of NPL)

Subsidiaries contributed total revenues of ₹8.48 million, total net loss after tax of ₹3.72 million, and total comprehensive loss of ₹2.19 million for the quarter. These results were not reviewed by any auditor and were provided by management.

IPO Completion

Subsequent to the quarter ended June 30, 2026, the Company completed its Initial Public Offering (IPO) of 1,77,88,442 equity shares of face value ₹2 each at an issue price of ₹988 per share (including share premium of ₹986 per share).

IPO Details:

  • Fresh issue: 15,21,261 equity shares aggregating ₹1,500.00 million
  • Offer for sale: 1,62,65,181 equity shares aggregating ₹16,070.00 million
  • Employee discount: ₹90 discount offered on 33,407 shares in employee reservation portion
  • Listing date: September 1, 2026 on NSE and BSE

The Company will provide an update on utilization of IPO proceeds towards objects of the fresh issue in the next reporting period.

Auditor's Review

The statutory auditors, SRBC & CO LLP, conducted a limited review and issued an unmodified report on both standalone and consolidated financial results. The review was conducted in accordance with SRE 2410 issued by ICAI.

Notes to Financial Results

1. Financial results prepared in accordance with Ind AS 34 and SEBI Listing Regulations

2. Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and unaudited figures up to December 31, 2025

3. Company primarily engaged in manufacturing and selling Pharmaceutical products, including APIs and Intermediates

4. No separate reportable segments as per Ind AS 108

5. Financial results available on BSE, NSE, and company website (www.symbiotec.com)